Drug Profile
MEDI 534
Alternative Names: MEDI-534; Parainfluenza/respiratory syncytial virus vaccine - AstraZeneca; RSV/PIV-3 vaccine - AstraZenecaLatest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parainfluenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 30 Jun 2012 Discontinued - Phase-I/II for Parainfluenza virus infections in Australia (Intranasal)
- 30 Jun 2012 Discontinued - Phase-I/II for Parainfluenza virus infections in Brazil (Intranasal)
- 30 Jun 2012 Discontinued - Phase-I/II for Parainfluenza virus infections in Canada (Intranasal)